Medicine guide
Nezglyal
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Leriglitazone
- Made by
- Minoryx Therapeutics S.L.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Nezglyal is indicated for the treatment of Cerebral Adrenoleukodystrophy (cALD) in males with Adrenoleukodystrophy (ALD) aged 2 to 12 years with non Gadolinium (Gd) enhancing lesions (i.e. Gd negative) in brain Magnetic Resonance Imaging (MRI), with a Neurological Functional Score (NFS) of 0 or 1.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Minoryx Therapeutics S.L. |
|---|---|
| Active substance | Leriglitazone |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A16AX23 · Digestion, stomach, diabetes and nutrition |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2026-09-21 |
| Last updated by the regulator | 2026-09-24 |
| EMA product number | EMEA/H/C/006693 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).